Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is a super drug-resistant pathogen for its multi-drug resistance, strong pathogenicity, high morbidity and mortality and is common in communities and hospitals in recent years. With the extensive use of various broad-spectrum antibiotics and the abuse of antimicrobial agents, MRSA strains have shown extensive resistance to conventional antibiotics such as vancomycin in recent years. The development of new drugs and new therapeutic regimens is the major clinical task for treatment of MRSA infection. Enhancing the antimicrobial effect of traditional antibiotics and reducing the resistance through combined usage of drugs are at present the feasible measures for clinical treatment. The article focuses on the drug combinations of anti-MRSA drugs such as vancomycin and the combination of traditional Chinese medicine and nanotechnology with antibiotics so as to provide reference for clinical medication and subsequent development of new drugs and new technology.